权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

mTORC1 and WNT in lung mesenchyme

肺间质中的 mTORC1 和 WNT

基本信息

批准号：
10278071
负责人：
VERA P KRYMSKAYA
金额：
$ 65.61万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-07-01 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10278071
关键词：
AGTR2 gene AXIN2 gene Address Age Alleles Alveolar Animal Genetics Animal Model Asthma Cells Chronic Chronic lung disease Clinical Trials Code Complex Data Disease Epithelial Epithelial Cells FRAP1 gene Female Gene Expression Genes Genetic Growth Hyperactivity Knowledge Lesion Ligands Link Lung Lung Lymphangioleiomyomatosis Lung diseases Lymphangioleiomyomatosis Mediating Mesenchymal Mesenchyme Modeling Mus Mutation Pathologic Pathway interactions Patients Pharmaceutical Preparations Phenotype Physiological Population Predisposition Pulmonary Pathology Role Side Signal Pathway Sirolimus Smooth Muscle Myocytes Structure TSC1/2 gene TSC2 gene Testing Therapeutic Intervention Tuberous sclerosis protein complex WNT Signaling Pathway Woman age related alveolar epithelium base beta catenin disease phenotype druggable target effective therapy fitness gain of function idiopathic pulmonary fibrosis insight lung injury molecular targeted therapies mouse development mouse model novel novel therapeutic intervention novel therapeutics pulmonary arterial hypertension pulmonary function sex single-cell RNA sequencing therapeutic target transcription factor translational study

项目摘要

Project Summary Lymphangioleiomyomatosis (LAM) is a rare fatal cystic lung disease due to bi-allelic inactivating mutations in tuberous sclerosis complex (TSC1/TSC2) genes coding for suppressors of the mechanistic target of rapamycin complex 1 (mTORC1). The origin of LAM cells is still unknown. We profiled a LAM lung compared to an age- and sex-matched healthy control lung as a hypothesis-generating approach to identify cell subtypes that are specific to LAM. Our single-cell RNA sequencing analysis reveals novel mesenchymal and transitional alveolar epithelial states unique to LAM lung. This analysis identifies a mesenchymal cell hub coordinating the LAM disease phenotype. Mesenchymal-restricted deletion of Tsc2 in the mouse lung produces a mTORC1-driven pulmonary phenotype, with a progressive disruption of alveolar structure, a decline in pulmonary function, increase of WNT ligands, and profound female-specific changes in mesenchymal and epithelial lung cell gene expression. Genetic inactivation of WNT signaling reverses age-dependent changes of mTORC1-driven lung phenotype, but WNT activation alone in lung mesenchyme is not sufficient for the development of mouse LAM- like phenotype. Our study identifies sex- and age-specific gene changes in the mTORC1-activated lung mesenchyme and establishes the importance of the WNT signaling pathway in the mTORC1-driven lung phenotype. Based on these data, we propose to test our hypothesis that mTORC1 hyperactivation in LAM cells dysregulates mTORC1-WNT signaling crosstalk which drives cystic airspace enlargement due to chronic activation of resident mesenchymal and alveolar epithelial cells. Our translational hypothesis states that dampening hyperactive mTORC1 and WNT signaling to basal physiological levels represents a potential opportunity to enhance the efficacy of rapalogs and potentially provide novel therapy for LAM patients. To test our hypothesis, we will specifically ask in: Aim 1: How does the small subset of LAM cells induce global pathological changes in the lung centered around lung mesenchymal cell hub? Aim 2: Does activation of mTORC1-WNT/?-catenin pathways in LAM lung mesenchyme dysregulate alveolar epithelial cell fitness? Aim 3: Will combined therapeutic targeting of the mTORC1-WNT/?-catenin pathways provide new treatment opportunities for LAM? The proposed studies will yield not only essential new insights into the role of TSC2-dependent mTORC1 activation and WNT signaling in LAM but also advance our understanding of how LAM lung mesenchymal cells orchestrate cystic lung damage. Our translational studies may also provide novel strategies for therapeutic intervention targeting hyperactive mTORC1 and WNT signaling pathways, which have not been tested for treatment of LAM.

项目总结